PTH Conjugate Starting Dose for Stable Calcium Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PTH therapies for hypoparathyroidism, such as Natpara and teriparatide, fail to maintain physiological PTH levels and serum calcium, leading to hypercalcemia, hypocalcemia, or hypercalciuria, and require cumbersome infusion pumps for continuous delivery, with no safe starting dose established for long-acting PTH conjugates.
Innovation Solution
A PTH conjugate reversibly linked to a polymeric moiety is administered at a starting dose ranging from 0.8 to 4.9 nmol/day, effectively suppressing endogenous PTH secretion while maintaining serum calcium levels without inducing hypercalcemia, allowing for a single daily injection to mimic continuous exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PTH therapies (Natpara, teriparatide) are used to treat hypoparathyroidism, then serum calcium can be normalized, but hypercalcemia, hypocalcemia, or hypercalciuria occurs and continuous exposure is required
Solution Approach 1:
The patent employs a dynamic dosing strategy with a starting dose range of 0.8 to 4.9 nmol/day that can be adjusted based on patient response. This dynamic approach allows the therapy to adapt to individual patient needs, maintaining physiological PTH levels while avoiding both hypercalcemia and hypocalcemia, thereby resolving the contradiction between reliable calcium control and administration convenience.
Solution Approach 2:
The patent changes the dosing parameter by establishing a specific starting dose range (0.8 to 4.9 nmol/day) for long-acting PTH conjugates. This parameter optimization enables single daily injection to achieve continuous exposure effects, eliminating the need for infusion pumps while maintaining stable serum calcium levels and preventing adverse effects.
2Reliability
If infusion pumps are used for continuous PTH delivery, then physiological PTH levels can be maintained, but device complexity and patient burden increase
Solution Approach 1:
The patent extracts the continuous delivery function from the infusion pump device by using long-acting PTH conjugates with extended half-lives. These conjugates provide sustained PTH exposure for 24 hours or more with a single daily injection, eliminating the need for complex infusion pump equipment while maintaining reliable continuous exposure.
Solution Approach 2:
The patent replaces the complex, reusable infusion pump system with simple, disposable single-daily injections of long-acting PTH conjugates. This approach maintains continuous therapeutic exposure without requiring expensive or complex medical devices, significantly reducing patient burden and device complexity.
3Productivity
If supraphysiological PTH doses are administered, then bone turnover can be stimulated, but hypercalcemia and suppression of endogenous PTH secretion occur
Solution Approach 1:
The patent optimizes the PTH dose parameter to a starting range of 0.8 to 4.9 nmol/day, which is sufficient to stimulate bone turnover and normalize serum calcium in hypoparathyroid patients without exceeding physiological limits. This parameter optimization prevents hypercalcemia and avoids excessive suppression of endogenous PTH secretion while maintaining therapeutic efficacy.
Solution Approach 2:
The patent incorporates feedback mechanisms through monitoring of serum calcium levels and endogenous PTH secretion. The dosing strategy adjusts based on patient response, ensuring that PTH levels remain physiological and that bone turnover is stimulated without causing harmful effects such as hypercalcemia or excessive suppression of endogenous PTH.
Data Source
Figure 1
AI summary
The present invention relates to a PTH conjugate, in which a PTH moiety is reversibly conjugated to a polymeric moiety or fatty acid-based moiety, or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said PTH conjugate or pharmaceutically acceptable salt thereof for use in the treatment, control, delay or prevention of a disease that can be treated, controlled, delayed or prevented with PTH, wherein the starting dose ranges from from 0.8 to 4.9 nmol/day and to the respective methods of treatment.